Ukraine is rapidly resuming its presence in the global clinical research arena. The country’s strategic efforts and favorable regulatory environment have positioned it as a preferred destination for conducting cutting-edge clinical trials.

The recent surge in clinical trial activity can be attributed to Ukraine’s commitment to streamlining regulatory processes, ensuring patient safety, and fostering collaborations between academia, industry, and research organizations. With the new legislation that came into force on the 22nd of March 2023, reducing the expert evaluation of a clinical trial application from 47 working days to 30 calendar days and shortening the time of its approval from 5 working days to 5 calendar days, Ukraine is offering a competitive advantage to sponsors worldwide.

There are a few important highlights GCT would like to share regarding the past year’s progress:

  • There have been no interruptions in patient enrollment in 2023;
  • 35 new clinical trials were approved in Q2-Q3 2022 and 7 in the 1st quarter in 2023;
  • 35 clinical trials have been initiated in Q2-Q3 2022 and 8 in the 1st quarter in 2023;
  • 11 clinical trials have been successfully resumed after being interrupted after February 24th, 2022, ensuring the continuity of vital research.

Dr. Dmytro Mnozhynskyy, GCT General Director based in Kyiv, commented on Ukraine’s resurgence, saying, “The revival of clinical research in Ukraine is a testament to our nation’s dedication to advancing medical science and contributing to global healthcare innovation. We are witnessing an influx of opportunities for patients to access cutting-edge treatments and therapies, which is incredibly promising.”

Amidst this recovery, Ukraine aims to attract a diverse range of clinical studies, spanning multiple therapeutic areas, including oncology, cardiology, neurology, and rare diseases. By doing so, the nation is poised to play a significant role in accelerating medical breakthroughs that address unmet medical needs.

As Ukraine rapidly regains its footing in the clinical research domain, stakeholders look forward to witnessing the positive impact on global healthcare advancements.